Company intelligence / Profile preview
Tenax Therapeutics
Chapel Hill, North Carolina, United Statestenaxthera.com ↗
- Ownership
- Public · TENX
- Employees
- ~6
- Development stage
- Phase 3
01
Overview
Tenax Therapeutics has two main programs in late-stage clinical development. The lead program TNX‑103 (oral levosimendan) for PH-HFpEF entered Phase 3 trials in early 2024. The LEVEL study aims to enroll over 230 patients across more than 50 sites in the US and Canada; topline data are expected in the second half of 2025. Imatinib for PAH was acquired via PH Precision Med and has previously shown efficacy but faced tolerability issues; a new formulation aims to address these concerns[5][7][9].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- small molecules (levosimendan, imatinib)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Phyxius Pharma, Inc. – North American rights to develop/commercialize levosimendan[9]. No major pharma partnerships disclosed as of May 2025.
04
Financials
- Market cap
- $43.2M
- Total revenue
- $0
- Enterprise value
- $-70.5M
Beyond the preview
Go deeper on Tenax Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenax Therapeutics.